Physician profile
Stacey B Gross
NPI 1760720221
$22,164.43
in general payments reported to CMS, 2019-2025
22 companies · $8,154 in 2025
The $8,154 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $11K · 2023: $1,699 · 2024: $467 · 2025: $8,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,738 · Travel and Lodging: $3,231 · Food and Beverage: $1,851 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,738.00 |
| Travel and Lodging | $3,230.69 |
| Food and Beverage | $1,850.90 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $10,292.31 | 2021-2025 | Optimizer, Optimizer |
| Edwards Lifesciences Corporation | $5,043.88 | 2021-2023 | |
| Cvrx, INC. | $4,843.35 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $276.39 | 2023-2025 | |
| Medtronic, INC. | $221.93 | 2025 | Affera Mapping System, Endurant Iis |
| Bridgebio Pharma, INC. | $196.62 | 2025 | Attruby |
| Amgen INC. | $155.35 | 2021-2024 | Repatha |
| Pfizer INC. | $155.32 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $150.42 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $144.87 | 2025 | |
| Janssen Pharmaceuticals, INC | $142.60 | 2022-2024 | Xarelto |
| Abiomed | $115.27 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $87.26 | 2022-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.33 | 2022-2024 | Jardiance |
| Scpharmaceuticals INC. | $46.81 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $44.35 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals Lp | $41.78 | 2024-2025 | Wainua |
| Heartflow, INC. | $39.88 | 2025 | |
| Boston Scientific Corporation | $35.23 | 2023 | Ekosonic |
| Novo Nordisk INC | $24.93 | 2024 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $20.41 | 2022 | |
| Abbott Laboratories | $18.14 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.